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OBJECTIVE This study was designed to examine whether or not adenovirus-mediated gene transfer of
C-type natriuretic peptide (CNP) can prevent coronary restenotic changes after balloon injury
in pigs in vivo.
BACKGROUND Gene therapy to prevent restenosis after percutaneous transluminal coronary angioplasty
(PTCA) might be useful but requires a method applicable for in vivo gene delivery into the
coronary artery as well as the efficient vector encoding a potent antiproliferative substance. We
tested whether the adenovirus-mediated gene transfer of CNP by use of an infiltrator
angioplasty balloon catheter (IABC) might prevent the coronary restenotic changes after
balloon injury.
METHODS Balloon angioplasty was performed in the left anterior descending and the left circumflex
coronary artery in pigs. Immediately after the balloon injury, adenovirus solution encoding
either CNP (AdCACNP) or b-galactosidase (AdCALacZ) gene was injected with IABC
into the balloon-injured coronary segments. Expression of CNP was assessed by immuno-
histochemical staining and cyclic guanosine 39,59-monophosphate (cGMP) measurement.
Coronary restenotic changes were evaluated by both angiographic and histological examinations.
RESULTS CNP was highly expressed in the media and the adventitia of the coronary artery at the
AdCACNP-transfected but not at the AdCALacZ-transfected segment. In the AdCALacZ-
transfected segment, vascular cGMP levels tended to be reduced as compared with the
untreated segment, whereas in the AdCACNP-transfected segment, vascular cGMP levels
were restored. Angiographic coronary stenosis was significantly less at the AdCACNP-
transfected than at the AdCALacZ-transfected segment. Histological examination revealed
that this was achieved primarily by the marked inhibition of the geometric remodeling of the
coronary artery by the CNP gene transfer.
CONCLUSIONS Adenovirus-mediated CNP gene transfer with the IABC system may be a useful gene therapy
to prevent restenosis after PTCA in vivo. (J Am Coll Cardiol 2000;35:1040–7) © 2000 by
the American College of Cardiology
Percutaneous transluminal coronary angioplasty (PTCA) is
a widely accepted treatment for coronary artery disease.
However, its usefulness is still limited by restenosis that
occurs in 30% to 40% of patients within three to six months
after the procedure (1). Restenosis is caused by complicated
mechanisms, including migration and proliferation of vas-
cular smooth muscle cells (VSMC) and subsequent neoin-
timal formation, geometric (constrictive) remodeling and
extracellular matrix formation (2–6). Although no effective
pharmacological therapy has yet been established to prevent
restenosis in humans, experimental studies have demon-
strated that gene therapy to inhibit VSMC proliferation and
migration after angioplasty may be useful (7–11). However,
most of those studies were performed in peripheral arteries
of rodents. Considering the clinical application of gene
therapy for the prevention of the restenosis, studies must be
performed in the arteries with the anatomical and patho-
physiological features similar to those of human coronary
arteries. It has been noted that there are many similarities in
coronary restenosis after balloon angioplasty in humans and
pigs (12,13).
We have previously demonstrated that adenovirus-
mediated gene transfer of dominant-negative H-ras (9), p21
(cyclin-dependent kinase inhibitor) (10) or C-type natri-
From the Department of Cardiovascular Medicine, Graduate School of Medical
Sciences, Kyushu University, Fukuoka, Japan.
This work was supported in part by grants from the Ministry of Education, Science,
Sports and Culture, Tokyo, Japan.
Manuscript received June 7, 1999; revised manuscript received October 15, 1999,
accepted November 19, 1999.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00625-7
uretic peptide (CNP) (11) into the rat carotid artery
suppresses the neointimal formation after balloon injury.
Among these candidates, CNP (14,15) seems to be prom-
ising because it is secreted by endothelial cells and modu-
lates vascular remodeling by a local autocrine/paracrine
mechanism (16,17). Indeed, the endothelium-derived pep-
tide has multiple effects, including dilation of blood vessels
(18,19) and inhibition of VSMC proliferation and migra-
tion (20,21) through cyclic guanosine 39,59-monophosphate
(cGMP) cascade. In human advanced atherosclerotic arter-
ies, endothelial CNP production is decreased (22), whereas
VSMC overexpress CNP-specific receptor, natriuretic pep-
tide receptor-B (NPR-B) (23). PTCA causes endothelial
injury resulting in the loss of endothelium-derived antipro-
liferative factors, including CNP and nitric oxide (NO),
both of which regulate the intracellular cGMP levels in
vascular walls (24,25). Therefore, gene therapy to overex-
press CNP may be effective for the site-specific treatment
against proliferative vascular diseases, including restenosis
after PTCA.
For the gene delivery system to the coronary artery, the
infiltrator angioplasty balloon catheter (IABC) has recently
been developed (26,27). It can deliver fluid directly into the
normal porcine coronary artery with .90% efficiency with
minimal vascular damage (26,27), and can be applied for an
in vivo gene delivery system into the coronary artery.
Thus, the purpose of the present study was to examine
whether or not local adenovirus-mediated gene transfer of
CNP with the IABC system is an effective gene therapy to
prevent the restenotic changes of the coronary artery after
balloon injury in pigs in vivo.
METHODS
This study was reviewed by the Committee of the Ethics on
Animal Experiments at the Kyushu University School of
Medicine and was carried out under the control of the
Guidelines for Animal Experiment at the Kyushu Univer-
sity School of Medicine and The Law (No. 105) and
Notification (No. 6) of the Japanese Government.
Experimental protocol. Experimental protocol is shown in
Figure 1. Fifteen animals (pigs) underwent coronary balloon
injury for both the left anterior descending (LAD) and the
left circumflex (LCX) coronary artery, followed by in vivo
gene transfer (CNP for one balloon-injured site and
b-galactosidase for another site in a randomized manner).
The expression of CNP was examined by both immuno-
staining for the protein (n 5 3) and measurement of
vascular cGMP levels (n 5 6) one week after the in vivo
gene transfer, when adenovirus-mediated gene expression
peaked (9–11), whereas coronary angiography and histolog-
ical examination were performed in the remaining six
animals three weeks after the gene transfer.
Adenovirus vector. As previously described (11),
replication-defective recombinant adenoviral vectors ex-
pressing Escherichia coli b-galactosidase (28) or rat CNP
(29) [the amino acid sequence of rat CNP is identical to that
in humans (30) and pigs (31)] were prepared under the
control of CA promotor composed of cytomegalovirus
enhancer and chicken b-action promoter. A recombinant
adenovirus was constructed by in vitro homologous recom-
binant in 293 cells. The desired recombinant adenovirus,
designated as AdCACNP, was purified by ultracentrifuga-
tion through a CsCl2 gradient followed by extensive dialysis.
The titer of the virus stock was assessed by a plaque
formation assay that used the 293 cells and was expressed in
plaque-forming units (pfu). We also used adenovirus vector
encoding b-galactosidase (AdCALacZ) as a control.
IABC system. IABC is an angioplasty balloon catheter
with 21 small nipples in three lines located on the surface of
the balloon connected to the drug delivery port (26,27).
This catheter has three lumens: one central lumen for the
angioplasty guide-wire, one for balloon inflation and an-
other for drug delivery (26,27). The balloon is 1.5 cm in
length and 3.5 mm in diameter, with the injection nipples
0.25 mm in height and 0.25 mm in diameter. The drug
delivery port was filled with virus solution until droplets
appeared through the needles before use.
Abbreviations and Acronyms
AdCACNP 5 adenovirus vector encoding CNP
AdCALacZ 5 adenovirus vector encoding b-
galactosidase
cGMP 5 cyclic guanosine 3’,5’-monophosphate
CNP 5 C-type natriuretic peptide
EEL 5 external elastic lamina
IABC 5 infiltrator angioplasty balloon catheter
IEL 5 internal elastic lamina
LAD 5 left anterior descending coronary artery
LCX 5 left circumflex coronary artery
NO 5 nitric oxide
NPR-B 5 natriuretic peptide-B
PTCA 5 percutaneous transluminal coronary
angioplasty
VSMC 5 vascular smooth muscle cells
Figure 1. Experimental protocol in the present study. AdCACNP
was transfected to the balloon-injured site for LAD (n 5 8) or
LCX (n 5 7), whereas AdCALacZ was transfected to the
remaining balloon-injured site in a randomized manner.
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Animal preparation. Domestic male pigs (two to three
months old, and weighing 25 to 30 kg) (Nihon Crea Inc.,
Tokyo, Japan) were sedated with intramuscular ketamine
hydrochloride (1.25 mg/kg) and were then anesthetized
with intravenous sodium pentobarbital (20 mg/kg). The
animals were then intubated and ventilated with room air,
and oxygen was supplemented via a positive-pressure respi-
rator (Shinano Inc., Tokyo, Japan). Under aseptic condi-
tions, the left carotid artery was surgically exposed, and a
10F sheath was inserted. After systemic heparinization
(10,000 U/body), a preshaped Judkins catheter (10F;
Medtronic Inc., Minneapolis, MN) was inserted into the
left carotid artery, and coronary angiography in a left
oblique view was performed using the Toshiba cineangiog-
raphy system (DG-15GB/ CAS-CA; Toshiba Medical
Inc., Tokyo, Japan). Electrocardiograms in leads I, II, III,
V1 and V6 were recorded (San-Ei Polygraph System; NEC,
Tokyo, Japan), and the arterial pressure was continuously
measured with a pressure transducer (Gould Inc., Cleve-
land, Ohio) connected to a Judkins catheter throughout the
experiment. After the virus solution was injected into the
coronary artery, angiography was repeated. Finally, the
carotid artery was ligated, the skin closed and the animals
allowed to recover from anesthesia.
Balloon injury followed by adenovirus-mediated in vivo
gene transfer into the porcine coronary artery. The cor-
onary artery was injured with a conventional balloon cath-
eter with a diameter 1.3 to 1.5 times larger than coronary
diameter by inflating it five times for 30 s at eight atmo-
spheres in both LAD and LCX. We previously confirmed
that the extent of coronary lesion induced by balloon injury
is comparable between LAD and LCX in porcine coronary
arteries (32). After this procedure, adenoviral gene transfer
was performed at the previously injured coronary segment.
IABC was advanced to the injured coronary artery followed
by the inflation of a 3.5-mm balloon at two atmospheres.
AdCALacZ (final titer, 4 3 108 pfu in 0.4 ml sorbitol-
added lactated Ringer’s saline) and AdCACNP (final titer,
4 3 108 pfu in 0.4 ml sorbitol-added lactated Ringer’s
saline) were randomly injected into the injured LAD and
LCX. After the gene transfer, IABC was deflated and
withdrawn, and the left carotid artery ligated.
Coronary angiography and coronary diameter measure-
ment. Coronary angiography in the left anterior oblique
view was performed before and three weeks after the gene
transfer. Coronary stenosis of the balloon-injured segments
was expressed as the percent decrease in the luminal
diameter compared with the mean diameter of the adjacent
proximal and distal normal coronary segments after the
intracoronary administration of nitroglycerin (10 mg/kg).
Histochemical analysis for b-galactosidase. Histochem-
ical analysis for b-galactosidase was performed one week
after the injection of AdCALacZ into the coronary arterial
wall. The animals were then killed with a lethal dose of
sodium pentobarbital, exsanguinated and then the coronary
artery was excised and fixed in phosphate-buffered saline
(containing 2% formaldehyde and 0.2% glutar-aldehyde) for
2 h at 4°C. After the fixation, the coronary arteries were
evaluated for LacZ expression by staining with a choromo-
genic substrate (X-gal; Wako Chemicals, Tokyo, Japan).
For the light microscopic examination, tissue samples were
embedded in paraffin after X-gal staining, sectioned into
slices 5 mm thick, mounted on glass slides and double-
stained with hematoxylin-eosin and nuclear fast red.
Histochemical analysis for CNP. Histochemical assays
for CNP were performed one week after the injection of
AdCACNP into the coronary artery. After the coronary
artery was excised, it was quickly frozen in OCT compound,
sectioned at 5 mm and subjected to immunohistostaining
with polyclonal antibody against CNP (Peninsula Lab.,
Belmont, California). Intact arteries and nonimmune rabbit
IgG were used as controls. Immunoreactive materials were
visualized by use of a biotinylated anti-rabbit IgG antibody
(Wako Chemicals, Tokyo, Japan), peroxidase-labeled
streptavidin and diaminobenzidine.
Radioimmunoassay for cGMP. To examine the produc-
tion of CNP, cGMP levels in a coronary artery were
measured in frozen sections from AdCACNP- and
Figure 2. Immunohistochemical staining of the porcine coronary artery one week after the adenovirus transfection in vivo. A,
Balloon-injured coronary segment with AdCALacZ transfection (double staining with X-gal and hematoxylin-eosin methods,
magnification 340). B and C, Balloon-injured coronary segments with AdCACNP transfection stained with anti-CNP antibody (brown)
(B) and nonimmune IgG (C).
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AdCALacZ-infected injured coronary segments, as well as
in those from uninjured normal coronary arteries. Vessels
from the animals were removed one week after the gene
transfer. All frozen tissues were homogenized in 0.1N
hydrochloric acid, and centrifuged. The supernatants were
assayed by radioimmunoassay.
Histological examination. Three weeks after the gene
transfer, the heart was removed and the left coronary arteries
were perfused with 6% formalin at the pressure of
120 mm Hg and fixed with formalin for one week. For the
light microscopic examination, tissue samples were embed-
ded in paraffin, sectioned into slices 5 mm thick, mounted
on glass slides and stained with hematoxylin-eosin and van
Gieson’s methods. With a photomicroscopic photograph
system (Microphot-FXA; Nikon Co., Tokyo, Japan), pic-
tures of coronary arteries were taken at 203 and 403
magnifications. In each specimen, lumen area and an area
encircled by the internal elastic lamina (IEL) or the external
elastic lamina (EEL) was measured with an automated
computer-based image analyzer (Digitizer KD4600;
Graphtec Corp., Yokohama, Japan) (32,33). The degree of
intimal thickening was assessed by the ratio of intimal area
to IEL area (% intima) (32,33). Coronary geometric (con-
strictive) remodeling was assessed by measuring the ratio of
the EEL, IEL and lumen areas at the balloon-injured
coronary segments to the mean of those of adjacent proxi-
mal and distal normal coronary segments (32,33). The
extent of balloon injury was assessed by the ratio of the
fractured IEL to the whole IEL length (32,33).
Data analysis. All results were measured by experienced
observers blinded to the origin of the samples, and expressed
as the mean 6 SEM. Paired data were analyzed by paired t
test, and multiple means were analyzed by one-way analysis
of variance, followed by Fisher’s post hoc test. A p , 0.05
was considered to be statistically significant.
RESULTS
Histochemical analysis for b-galactosidase and CNP.
One week after the balloon injury and gene transfection, the
expression of b-galactosidase was noted in the media and
the adventitia at the AdCALacZ-transfected site (especially
around the nipple sites), while at the AdCACNP-
transfected site, the expression of CNP was also noted, but
in a more diffuse manner, in the media (VSMC) and the
adventitia (fibroblasts) of the porcine coronary artery (Fig.
2). No CNP immunoreactivity was noted in the coronary
segment adjacent to the AdCACNP-transfected site (data
not shown).
Radioimmunoassay for cGMP. Vascular cGMP levels
tended to be reduced one week after the balloon injury at the
AdCALacZ-transfected site compared with those in the
uninjured normal site (Fig. 3). By contrast, the cGMP levels
at the AdCACNP-transfected site were restored to more
than those in the uninjured normal site (Fig. 3).
Coronary angiography and coronary diameter measure-
ment. Three weeks after the balloon injury and gene
transfection, the development of angiographic coronary
stenosis was more significantly suppressed at the
AdCACNP-transfected site than at the AdCALacZ-
transfected site (Figs. 4 and 5).
Histological examination. The histological examination
showed that the extent of the fractured IEL was comparable
between the AdCALacZ-transfected (11 6 2%) and the
AdCACNP-transfected sites (11 6 2%). The EEL, IEL
and lumen areas were significantly reduced by the balloon
injury at the AdCALacZ-transfected sites, whereas the
reductions were markedly inhibited at the AdCACNP-
transfected sites (Figs. 6 and 7). By contrast, the extent of
neointimal formation was mild, and no significant difference
was noted between the AdCALacZ- and the AdCACNP-
transfected site (%intima, 18 6 4% and 13 6 3%, respec-
tively). There was a significant exponential correlation
between the extent of angiographic stenosis and that of
histological lumen narrowing (Fig. 8).
DISCUSSION
The major findings of the present study were that local in
vivo gene delivery with IABC was applicable for the
coronary artery, and local overexpression of CNP signifi-
cantly suppressed the geometric remodeling of the coronary
artery after balloon injury in pigs in vivo. To the best of our
knowledge, this is the first report that demonstrates the
usefulness of the adenovirus-mediated in vivo gene transfer
of CNP into the porcine coronary artery for the prevention
of restenosis after coronary angioplasty.
CNP as a promising candidate of gene therapy. Endog-
enous CNP is secreted from vascular endothelial cells,
acting as an endothelium-derived relaxing and antiprolif-
erative peptide (17,20,21). Unlike ANP and BNP, which
regulate body fluids and blood pressure as cardiac hormones
Figure 3. cGMP levels in balloon-injured porcine coronary arter-
ies. cGMP levels (pmol/mg protein) one week after the gene
transfer are shown for normal coronary arteries (Normal), injured
coronary arteries transfected with AdCALacZ (LacZ) or AdC-
ACNP (CNP). *p , 0.05 vs. AdCALacZ-transfected site.
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(34), CNP is involved in the vascular natriuretic peptide
system, modulating the phenotype of VSMC, and thus
regulating vascular remodeling through activation of cGMP
cascade (17,20,21). In the present study, the expression of
CNP was highly detectable by the immunohistochemical
staining in the media and the adventitia of the porcine
coronary artery after the transfection with AdCACNP. It is
considered that the production of CNP from VSMC,
fibroblast or other inflammatory cells resulted in the increase
in vascular cGMP levels in the coronary artery. Although
other CNP-mediated mechanisms might also be involved in
the inhibition of vascular remodeling in this study, it is
highly possible that CNP/cGMP cascade primarily regu-
lated the vascular remodeling by inhibiting the proliferation
and migration of VSMC.
The advantages of CNP as a candidate for gene therapy
include its local but diffusable effect. Indeed, in the present
study, the biological effects of CNP were localized in the site
at which AdCACNP was transfected without causing any
systemic effect such as hypotension or natriuresis (data not
shown). The short half-life of CNP in the plasma (35) and
the overexpression of CNP receptor (NPR-B) in injured
artery (22,23) may explain the site-specific effects of CNP.
Unlike the expression of control gene (AdCALacZ), the
immunoreactivity of CNP was noted throughout the media
and the adventitia, indicating that CNP, once produced and
secreted by infected cells (e.g., VSMC and fibroblasts),
diffused throughout the vessel wall and exerted its antipro-
liferative effect throughout the vessel wall. NO may share
the same characteristics as CNP. Indeed, Varenne et al. (36)
recently reported that local adenovirus-mediated transfer of
eNOS reduced luminal narrowing after coronary angio-
plasty in pigs. However, overexpression of eNOS may have
some limitations because it has been recently demonstrated
that serious vascular smooth muscle tolerance to NO occurs
in transgenic mice overexpressing eNOS (37).
Vascular remodeling vs. neointimal formation. It is now
widely accepted that luminal narrowing after coronary
angioplasty is caused primarily by geometric (constrictive)
remodeling but not by neointimal formation (2–5). We have
previously demonstrated that adventitial inflammatory/
proliferative responses play an important role in the patho-
genesis of the geometric remodeling in pigs in vivo (32,38).
Indeed, when tyrosine kinases, which are the key step for
proliferative responses, were inhibited by the adventitial
Figure 4. Coronary arteriograms after intracoronary administration of nitroglycerin (10 mg/kg) in a pig before (A) and three weeks after
(B) the gene transfer in vivo. The white arrow indicates the site transfected with AdCALacZ (LacZ), and the black arrow indicates the
site transfected with AdCACNP (CNP).
Figure 5. Quantitative analysis of coronary diameter three weeks
after the gene transfer in vivo (n 5 6). All individual data are
plotted. LacZ: AdCALacZ-transfected site; CNP: AdCACNP-
transfected site.
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treatment with a specific inhibitor, the development of
geometric remodeling caused by either balloon injury (32) or
platelet-derived growth factor (38) was markedly inhibited.
Thus, the adventitial delivery of an antiproliferative gene
with IABC in the present study appears to be a reasonable
approach to prevent the geometric remodeling. By contrast,
the neointimal formation was mild and apparently did not
significantly contribute to the luminal narrowing in the
present model of coronary angioplasty. However, it remains
to be examined why the neointimal formation was not
significantly inhibited at the AdCACNP-transfected site.
IABC as a gene delivery system into the coronary artery
in vivo. The volume of adenovirus vector used in the
present study with IABC (4 3 108 pfu in 0.4 ml) was
one-tenth of that used in the previous studies with a
percutaneous balloon catheter (39,40), demonstrating a
high efficiency of the IABC system for in vivo gene transfer
into the coronary artery. Indeed, it is important for this type
of gene therapy to use a small amount of vector solution to
avoid the local inflammation and systemic responses
(26,27). A more sophisticated catheter needs to be devel-
oped for more efficient gene delivery into the coronary artery
in vivo.
Figure 6. Histology of the coronary artery segments transfected with AdCALacZ (A) or AdCACNP (C) after the angioplasty and of the
untreated segments adjacent to AdCALacZ-transfected segment (B) and AdCACNP-transfected segment (D). Vascular remodeling is
suppressed at the AdCACNP-transfected segment compared with the AdCALacZ-transfected segment. Note that the extent of the
fractured IEL caused by angioplasty was comparable between the AdCALacZ- and the AdCACNP-transfected sites.
Figure 7. Changes of the cross-sectional areas of porcine coronary
arteries three weeks after the gene transfer. The reduction of the
cross-sectional area at the treated segment is expressed in percent
change compared with the mean cross-sectional area of the
adjacent proximal and distal normal coronary segments. EEL,
external elastic lamina area; IEL, internal elastic lamina area;
Lumen, lumen area; LacZ, AdCALacZ-transfected site; CNP,
AdCACNP-transfected site. *p , 0.05 vs. AdCALacZ-
transfected site.
Figure 8. Correlation between the extent of angiographic coronary
stenosis and that of histological lumen narrowing. There was a
significant exponential correlation between the two values.
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Limitations of the present study. Several limitations could
be raised for the present study. First, the present study was
performed in the otherwise normal porcine coronary artery.
In the atherosclerotic coronary artery with an increased wall
thickness, the present approach with IABC may have a
limitation; however, the expression of diffusable antiprolif-
erative factor (e.g., CNP, NO) with a more sophisticated
infiltrator catheter may overcome this problem in the future.
Second, the use of adenovirus vector induces an intrinsic
immunity against the vector, and therefore repeated use of
the present strategy may be limited. Thus, the inhibition of
such an immunity by a suitable method (e.g., temporal use
of immunosuppressant) and the development of a less
immunogenic vector remain to be examined (41). Third, the
use of IABC itself may cause a greater vascular injury than
conventional balloon catheters. However, the extent of
vascular injury (fractured IEL) was comparable between the
present study with IABC and the previous study with a
conventional balloon catheter (32). Indeed, IABC is now
widely used for coronary intervention in European countries
without any major complications (27). Fourth, the extent of
neointimal formation was too mild to examine the inhibi-
tory effect of CNP. The greater extent of balloon injury
would also reveal the inhibitory effect of CNP gene transfer
on the neointimal formation.
In summary, the present study demonstrated that the
local adenovirus-mediated transfer of CNP suppresses vas-
cular remodeling in porcine coronary arteries in vivo. This
strategy might also be useful to prevent restenosis after
PTCA in humans.
Reprint requests and correspondence: Dr. Hiroaki Shimokawa,
Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kyushu University 3-1-1 Maidashi, Higashi-ku,
Fukuoka 812-8582, Japan. E-mail: shimo@cardiol.med.kyushu-
u.ac.jp.
Acknowledgments
We thank Y. Takamura for cooperation in this study, and S.
Tomita, E. Gunshima and M. Sonoda for their excellent
technical assistance.
REFERENCES
1. Popma JJ, Topol EJ. Factors influencing restenosis after coronary
angioplasty. Am J Med 1990;88:16N–24N.
2. Currier JW, Faxon DP. Restenosis after percutaneous transluminal
coronary angioplasty: have we been aiming at the wrong target? J Am
Coll Cardiol 1995;25:516–20.
3. Post MJ, Borst C, Kuntz RE. The relative importance of arterial
remodeling compared with intimal hyperplasia in lumen renarrowing
after balloon angioplasty. A study in the normal rabbit and the
hypercholesterolemic Yucatan micropig. Circulation 1994;89:2816–
21.
4. Lafont A, Guzman LA, Whitlow PL, et al. Restenosis after experi-
mental angioplasty. Intimal, medial, and adventitial changes associated
with constrictive remodeling. Circ Res 1995;76:996–1002.
5. Andersen HR, Maeng M, Thorwest M, Falk E. Remodeling rather
than neointimal formation explains luminal narrowing after deep vessel
wall injury: insights from a porcine coronary (re)stenosis model.
Circulation 1996;93:1716–24.
6. Strauss BH, Chisholm RJ, Keeley FW, et al. Extracellular matrix
remodeling after balloon angioplasty injury in a rabbit model of
restenosis. Circ Res 1994;75:650–8.
7. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo
by direct gene transfer into the arterial wall. Science 1990;249:1285–8.
8. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for
vascular proliferative disorders with a constitutively active form of the
retinoblastoma gene product. Science 1995;267:518–22.
9. Ueno H, Yamamoto H, Ito S, Li JJ, Takeshita A. Adenovirus-
mediated transfer of a dominant-negative H-ras suppresses neointimal
formation in balloon-injured arteries in vivo. Arterioscler Thromb
Vasc Biol 1997;17:898–904.
10. Ueno H, Masuda S, Nishio S, et al. Adenovirus-mediated transfer of
cyclin-dependent kinase inhibitor-p21 suppresses neointimal forma-
tion in the balloon-injured rat carotid arteries in vivo. Ann NY Acad
Sci 1997;811:401–11.
11. Ueno H, Haruno A, Morisaki N, et al. Local expression of C-type
natriuretic peptide markedly suppresses neointimal formation in rat
injured arteries through an autocrine/paracrine loop. Circulation 1997;
96:2272–9.
12. Muller DW, Ellis SG, Topol EJ. Experimental models of coronary
artery restenosis. J Am Coll Cardiol 1992;19:418–32.
13. Karas SP, Gravanis MB, Santoian EC, et al. Coronary intimal
proliferation after balloon injury and stenting in swine: an animal
model of restenosis. J Am Coll Cardiol 1992;20:467–74.
14. Komatsu Y, Nakao K, Suga S, et al. C-type natriuretic peptide (CNP)
in rats and humans. Endocrinology 1991;129:1104–6.
15. Ogawa Y, Nakao K, Nakagawa O, et al. Human C-type natriuretic
peptide. Characterization of the gene and peptide. Hypertension
1992;19:809–13.
16. Barletta G, Lazzeri C, Vecchiarino S, et al. Low-dose C-type
natriuretic peptide does not affect cardiac and renal function in
humans. Hypertension 1998;31:802–8.
17. Itoh H, Suga S, Ogawa Y, et al. Significance of vascular natriuretic
peptide system in vascular remodeling in humans and its application to
gene therapy. Ann New York Acad Sci 1997;811:533–41.
18. Wei CM, Aarhus LL, Miller VM, Burnett JC, Jr. Action of C-type
natriuretic peptide in isolated canine arteries and veins. Am J Physiol
1993;264:H71–3.
19. Wei CM, Hu S, Miller VM, Burnett JC, Jr. Vascular actions of C-type
natriuretic peptide in isolated porcine coronary arteries and coronary
vascular smooth muscle cells. Biochem Biophys Res Commun 1994;
205:765–71.
20. Doi K, Itoh H, Ikeda T, et al. Adenovirus-mediated gene transfer of
C-type natriuretic peptide causes G1 growth inhibition of cultured
vascular smooth muscle cells. Biochem Biophys Res Commun 1997;
239:889–94.
21. Ikeda M, Kohno M, Yasunari K, et al. Natriuretic peptide family as a
novel antimigration factor of vascular smooth muscle cells. Arterioscler
Thromb Vasc Biol 1997;17:731–6.
22. Naruko T, Ueda M, van der Wal AC, et al. C-type natriuretic peptide
in human coronary atherosclerotic lesions. Circulation 1996;94:
3103–8.
23. Koller KJ, Lowe DG, Bennett GL, et al. Selective activation of the B
natriuretic peptide receptor by C-type natriuretic peptide (CNP).
Science 1991;252:120–3.
24. Garg UC, Hassid A. Nitric oxide-generating vasodilators and
8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and
proliferation of cultured rat vascular smooth muscle cells. J Clin Invest
1989;83:1774–7.
25. Marumo T, Nakaki T, Hishikawa K, et al. Natriuretic peptide-
augmented induction of nitric oxide synthase through cyclic guanosine
3’,5’-monophosphate elevation in vascular smooth muscle cells. En-
docrinology 1995;136:2135–42.
26. Barath P, Popov A, Dillehay GL, Matos G, McKiernan T. Infiltrator
angioplasty balloon catheter: a device for combined angioplasty and
intramural site-specific treatment. Cathet Cardiovasc Diagn 1997;41:
333–41.
27. Pavlides GS, Barath P, Maginas A, et al. Intramural drug delivery by
direct injection within the arterial wall: first clinical experience with a
novel intracoronary delivery infiltrator system. Cathet Cardiovasc
Diagn 1997;41:287–92.
1046 Morishige et al. JACC Vol. 35, No. 4, 2000
CNP Gene Transfer and Coronary Restenosis March 15, 2000:1040–7
28. Ueno H, Li JJ, Tomita H, et al. Quantitative analysis of repeat
adenovirus-mediated gene transfer into injured canine femoral arteries.
Arterioscler Thromb Vasc Biol 1995;15:2246–53.
29. Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and
sequence analysis of a cDNA encoding a precursor for rat C-type
natriuretic peptide (CNP). FEBS Lett 1990;276:209–13.
30. Tawaragi Y, Fuchimura K, Tanaka S, et al. Gene and precursor
structures of human C-type natriuretic peptide. Biochem Biophys Res
Commun 1991;175:645–51.
31. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic
peptide (CNP): a new member of natriuretic peptide family identified
in porcine brain. Biochem Biophys Res Commun 1990;168:863–70.
32. Fukumoto Y, Shimokawa H, Kozai T, et al. Tyrosine kinase inhibitor
suppresses the (re)stenotic changes of the coronary artery after balloon
injury in pigs. Cardiovasc Res 1996;32:1131–40.
33. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a
specific tyrosine kinase inhibitor with biodegradable stent suppresses
the restenotic changes of the coronary artery in pigs in vivo. J Am Coll
Cardiol 1998;32:273–9.
34. Espiner EA. Physiology of natriuretic peptides. J Intern Med 1994;
235:527–41.
35. Brandt RR, Mattingly MT, Clavell AL, Barclay PL, Burnett JC, Jr.
Neutral endopeptidase regulates C-type natriuretic peptide metabo-
lism but does not potentiate its bioactivity in vivo. Hypertension
1997;30:184–90.
36. Varenne O, Pislaru S, Gillijns H, et al. Local adenovirus-mediated
transfer of human endothelial nitric oxide synthase reduces luminal
narrowing after coronary angioplasty in pigs. Circulation 1998;98:
919–26.
37. Ohashi Y, Kawashima S, Hirata K, et al. Hypotension and reduced
nitric oxide-elicited vasorelaxation in transgenic mice overexpressing
endothelial nitric oxide synthase. J Clin Invest 1998;102:2061–71.
38. Kozai T, Shimokawa H, Fukumoto Y, et al. Tyrosine kinase inhibitor
markedly suppresses the development of coronary lesions induced by
chronic treatment with platelet-derived growth factor in pigs in vivo.
J Cardiovasc Pharmacol 1997;295: 536–45.
39. French BA, Mazur W, Ali NM, et al. Percutaneous transluminal in
vivo gene transfer by recombinant adenovirus in normal porcine
coronary arteries, atheroscle-rotic arteries, and two models of coronary
restenosis. Circulation 1994;90:2402–13.
40. Chapman GD, Lim CS, Gammon RS, et al. Gene transfer into
coronary arteries of intact animals with a percutaneous balloon
catheter. Circ Res 1992;71:27–33.
41. Kullo IJ, Simari RD, Schwartz RS. Vascular gene therapy. From bench
to bedside. Arterioscler Throm Vasc Biol 1999;19:196–207.
1047JACC Vol. 35, No. 4, 2000 Morishige et al.
March 15, 2000:1040–7 CNP Gene Transfer and Coronary Restenosis
